Kymera Therapeutics

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting

Poster #18, Late-Breaking Research: Experimental and Molecular Therapeutics (Session 2)  to be Presented April 3, 2019 8:00 AM – 12:00 PM Cambridge, Mass. (March 29, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines